Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

This study tests a combination of durvalumab (an immunotherapy drug) and a procedure called intraductal radiofrequency ablation (ID-RFA) — which uses heat energy delivered inside the bile duct to destroy tumor tissue — for people with a bile duct cancer called extrahepatic cholangiocarcinoma. **You may be eligible if...** - You are 18 years old or older - You have been diagnosed with extrahepatic cholangiocarcinoma (cancer of the bile ducts outside the liver) - Your cancer is not surgically removable - You are well enough to undergo the procedures and follow-up visits **You may NOT be eligible if...** - You have significant heart, liver, or kidney problems - You have active autoimmune disease or are on immunosuppressive medications - You have previously received certain cancer treatments that are not allowed in this study - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.